• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

18.27 +0.32 (+1.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx (AMLX) Q2 Net Loss Narrows 43% ↗
August 07, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted ↗
August 07, 2025
Amylyx Pharmaceuticals reports Q2 2025 earnings with EPS in line, $41.4M net loss. Market reaction muted as focus remains on clinical-stage pipeline updates. 
Via Chartmill
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
August 07, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
May 08, 2025
 
Via Benzinga
News headline image
Exploring Amylyx Pharma's Earnings Expectations ↗
May 07, 2025
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
July 31, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 14, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery ↗
July 14, 2025
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia. 
Via Benzinga
News headline image
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial ↗
July 13, 2025
The company is advancing the treatment into a Phase 3 study with results expected in 2026. 
Via Stocktwits
News headline image
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
July 13, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
July 08, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 07, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Shares in Amylyx Pharmaceuticals Soared This Week ↗
June 27, 2025
Via The Motley Fool
News headline image
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market ↗
June 24, 2025
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
News headline image
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday ↗
June 24, 2025
 
Via Benzinga
News headline image
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗
June 24, 2025
 
Via Benzinga
News headline image
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
June 24, 2025
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
June 03, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 21, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome
May 12, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results
May 08, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
May 07, 2025
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences
May 07, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
May 07, 2025
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
May 01, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia
April 30, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
April 09, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
April 02, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap